

Oncology Intelligence Report

Immuno-Oncology · ADCs · CAR-T · Population Epidemiology · Vision 2030

● LIVE INGEST

Last refresh — 07 May 2026 23:49:38Z

Window — last 90 days

Pipeline — tools/scout-ingest

<p>TRACKED SIGNALS</p> <p>1,777</p> <p>Public, source-cited</p>	<p>SOURCES ACTIVE</p> <p>5 / 8</p> <p>CT.gov, PubMed, SEC, SEER live</p>	<p>COMPANIES MONITORED</p> <p>50</p> <p>Atlas-linked dossiers</p>	<p>CRITICAL / HIGH SEVERITY</p> <p>128</p> <p>Material signals (90d)</p>
--	---	--	---

RISK REGISTER · THE COST OF SEEING LATE Adversarial verification scope

Three exposures every oncology portfolio carries today.

Reimbursement Cycle Risk

Keytruda and Opdivo label expansions, Lynparza maintenance positioning, and ADC pricing decisions in flight across the 2025–2026 cycle reshape roughly \$200B in run-rate revenue. PubMed indexed signals carry the early-warning footprint.

1,000

Population Outcomes Risk

Bottom-quintile cancer sites — pancreatic, esophageal, liver, lung — carry under 25% five-year relative survival per SEER. The patients are the market. Indication strategy that ignores the population vector mis-prices the asset.


30

Sovereign Procurement Risk

King Faisal Specialist Hospital & Research Centre (Riyadh) and Cleveland Clinic Abu Dhabi anchor GCC oncology procurement. Vision 2030 ministry-scale capital cycles close every 18 months — missing one means missing a cycle.

2 / 50

What we are watching



Top 10 by severity and recency

PUBMED CRITICAL 2026-03-04

Large cohort studies assessing sex-specific associations between anthropometric indices and liver cancer death.

Yang DN

Large cohort studies assessing sex-specific associations between anthropometric indices and liver cancer death.

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

Arginine deprivation induces prolonged autophagy activation and ROS-dependent cell death in glioblastoma multiforme.

Abdelkhalik M

Arginine deprivation induces prolonged autophagy activation and ROS-dependent cell death in glioblastoma multiforme.

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

Adjuvant immunotherapy plus chemotherapy and maintenance immunotherapy for pulmonary lymphoepithelioma-like carcinoma with hepatitis B virus infection, KRAS mutation and high expression of programmed death ligand 1: A case report.

Zhu J

Adjuvant immunotherapy plus chemotherapy and maintenance immunotherapy for pulmonary...

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

Expression of Programmed Death-Ligand 1 in Cervical Cancer: Correlation With Histologic Subtypes and Clinicopathological Features.

Vahedpoor Z

Expression of Programmed Death-Ligand 1 in Cervical Cancer: Correlation With Histologic Subtypes and...

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

Fatal Emphysematous Tonsillopharyngitis With Laryngocele Involvement Revealing Acute Myeloid Leukemia M5 Subtype: A Previously Undescribed Presentation.

Al Kiswani S

Fatal Emphysematous Tonsillopharyngitis With Laryngocele Involvement Revealing Acute Myeloid Leukemia M5 Subtyp...

PubMed (NCBI E-utilities) ↗

CLINICALTRIALS CRITICAL 2021-01-25

A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1...

ClinicalTrials.gov ↗

FDA

CRITICAL

2016-08-17

HeartWare Ventricular Assist System (HVAD), US product: Model No.: I103; and International Product: Model No.: I104XX. Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. Designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter.

HeartWare, Inc

Foreign material found within the driveline connector of the HVAD Pump that could cause increased impedance resultin...

[U.S. Food & Drug Administration](#)

FDA

CRITICAL

2016-06-08

HeartWare Ventricular Assist System Controller Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. The HVAD is designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter

Heartware, Inc.

Loose connector ports in controller body.

[U.S. Food & Drug Administration](#)

FDA

CRITICAL

2009-09-22

Penumbra Neuron Delivery Catheter 070, percutaneous catheter, catalog numbers PND6F070I058, PND6F070956, PND6F070I058M, and PND6F070956M; manufactured by Penumbra, Inc., Alameda, CA. Indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.

Penumbra Inc.

Failure-- product can kink or ovalize, which may result in difficulty in catheter advancement or delivery of other...

[U.S. Food & Drug Administration](#)

PUBMED

HIGH

2026-05-15

Leisure-time physical activity modulates associations of sarcopenia and functional disability with mortality in older adults.

Zhu Z

Leisure-time physical activity modulates associations of sarcopenia and functional disability with mortality in older...

[PubMed \(NCBI E-utilities\)](#)

Approval and reimbursement watchlist

FDA & REIMBURSEMENT · 2025-2026

Checkpoint inhibitor label expansion, ADC class pricing, and CAR-T site-of-care policy are reshaping oncology economics.

Coverage and formulary decisions on PD-1/PD-L1 inhibitors across new tumor settings, antibody-drug conjugate pricing in HER2-low and triple-negative breast disease, and CAR-T outpatient site-of-care policy are in active rewrite across FDA, CMS, and the major commercial PBMs. AimwellBio's FDA, CMS LCD, and manufacturer-pipeline ingests are in calibration; full coverage activates on the next refresh cycle. Manufacturer commentary, MAC bulletins, and proposed-policy comment periods will populate this surface as each indexer comes online.

30 cancer-site stat facts under continuous tracking.

POPULATION VECTOR · NCI SEER

SEER is the foundational population-epidemiology layer for oncology decisions. AimwellBio integrates it directly into the signal pool.

The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute is the public ground-truth for U.S. cancer incidence, mortality, five-year relative survival, prevalence, and lifetime risk. AimwellBio pulls 30 site-level Cancer Stat Facts directly into the indication-aware indexer — with origin URLs, fetch timestamps, and reproducible claims for every fact.

Most oncology dashboards treat population data as a static appendix. AimwellBio treats it as a live signal class on equal footing with PubMed, SEC, and ClinicalTrials.gov. The cancers with the highest mortality and lowest survival — pancreatic, esophageal, liver, lung — should be where indication strategy starts, not where it ends up after the safer markets are picked.

30

Cancer-site stat facts continuously tracked

5

Population metrics per site — incidence, mortality, 5-yr survival, prevalence, lifetime risk

<25%

Five-year survival across the bottom-quintile sites

100%

Source-cited — every claim links to seer.cancer.gov

MATERIAL SITES · HIGHEST MORTALITY / LOWEST SURVIVAL

<p>Lung & Bronchus</p> <p>NCI SEER · Cancer Stat Facts</p> <p>SEER</p>	<p>Pancreas</p> <p>NCI SEER · Cancer Stat Facts</p> <p>SEER</p>	<p>Liver & IBD</p> <p>NCI SEER · Cancer Stat Facts</p> <p>SEER</p>	<p>Esophagus</p> <p>NCI SEER · Cancer Stat Facts</p> <p>SEER</p>	<p>Colorectal</p> <p>NCI SEER · Cancer Stat Facts</p> <p>SEER</p>
---	--	---	---	--

Monitored issuers and operators


Cleveland Clinic Abu Dhabi Oncology Abu Dhabi, AE GCC	King Faisal Specialist Hospital Oncology Riyadh, SA KSA	2seventy bio Cambridge, MA BIOTECH
AbbVie Oncology ABBV North Chicago, IL BIGPHARMA	Adaptimmune ADAP Abingdon, UK BIOTECH	Allogene Therapeutics ALLO South SF, CA BIOTECH
ALX Oncology ALXO South SF, CA EMERGING	Arcus Biosciences RCUS Hayward, CA BIOTECH	Arvinas ARVN New Haven, CT EMERGING
Astellas Oncology Tokyo, JP BIGPHARMA	AstraZeneca Oncology AZN Cambridge, UK BIGPHARMA	Autolus Therapeutics AUTL London, UK BIOTECH
Bayer Oncology Leverkusen, DE BIGPHARMA	Beam Therapeutics BEAM Cambridge, MA BIOTECH	BeiGene BGNE Beijing, CN BIGPHARMA
BioMarin BMRN San Rafael, CA BIOTECH	BioNTech BNTX Mainz, DE BIOTECH	Bluebird Bio Somerville, MA BIOTECH
Blueprint Medicines BPNC Cambridge, MA BIOTECH	Bristol Myers Squibb BMY Princeton, NJ BIGPHARMA	Caribou Biosciences CRBU Berkeley, CA BIOTECH
CRISPR Therapeutics CRSP Zug, CH BIOTECH	Daiichi Sankyo Oncology Tokyo, JP BIGPHARMA	Editas Medicine EDIT Cambridge, MA BIOTECH
Eisai Oncology Tokyo, JP BIGPHARMA	Exelixis EXEL Alameda, CA BIOTECH	Genmab GMAB Copenhagen, DK BIOTECH
GSK Oncology GSK London, UK BIGPHARMA	Hutchmed HCM Shanghai, CN BIOTECH	IDEAYA Biosciences IDYA South SF, CA EMERGING

ImmunoGen (AbbVie) ABBV Waltham, MA BIOTECH	Intellia Therapeutics NTLA Cambridge, MA BIOTECH	Iovance Biotherapeutics IOVA San Carlos, CA BIOTECH
Janssen Oncology (J&J) Raritan, NJ BIGPHARMA	Jazz Pharmaceuticals JAZZ Dublin, IE BIOTECH	Karyopharm Therapeutics KPTI Newton, MA BIOTECH
Merck Oncology (Keytruda) MRK Rahway, NJ BIGPHARMA	Mirati Therapeutics MRTX San Diego, CA BIOTECH	Moderna Oncology MRNA Cambridge, MA BIOTECH
Novartis Oncology NVS Basel, CH BIGPHARMA	Nuvation Bio NUVB New York, NY EMERGING	Pfizer Oncology PFE New York, NY BIGPHARMA
Recursion Pharmaceuticals RXRX Salt Lake City, UT EMERGING	Relay Therapeutics RLAY Cambridge, MA EMERGING	Replimune REPL Woburn, MA BIOTECH
Roche Oncology Basel, CH BIGPHARMA	Sanofi Oncology SNY Paris, FR BIGPHARMA	Seagen (Pfizer) PFE Bothell, WA BIOTECH
Servier Suresnes, FR BIGPHARMA	Takeda Oncology TAK Cambridge, MA BIGPHARMA	

06 - 90-DAY SIGNAL TIMELINE

Hover any bar for week detail

Volume & cadence of public disclosure



METHODOLOGY

This report is generated from a live ingest pipeline (`tools/scout-ingest`). Sources: ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, NCI SEER Cancer Stat Facts (live), with FDA openFDA, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages in calibration. Updated 07 May 2026 23:49:38Z. Every signal carries source URL and fetch timestamp; click any card to view origin.

Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.

SEER positioning. SEER provides free public NCI cancer-statistics data. AimwellBio adds adversarial verification, indication-aware filtering, and source-citation on top of the public layer. Premium linked datasets — SEER-Medicare, SEER-CAHPS, SEER-MHOS — are reserved for the paying tier when the question deserves them.

Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA. Sovereign-tagged institutions (KSA, GCC, MENA) reflect publicly observable regional headquarters; ministry-procurement detail is reserved for the partner intelligence surface.